Valuation: Abivax

Market Cap 10.59B 12.11B 9.77B 9.03B 17.12B 1,155B 17.41B 117B 45.85B 569B 45.48B 44.49B 1,956B P/E 2026 *
-33.6x
P/E 2027 * -37.7x
Enterprise Value 9.65B 11.04B 8.9B 8.22B 15.6B 1,053B 15.87B 106B 41.78B 519B 41.44B 40.54B 1,783B EV / Sales 2026 *
129x
EV / Sales 2027 * 119x
Free-Float
92.81%
Yield 2026 *
-
Yield 2027 * -
1 day-2.28%
1 week-6.83%
Current month+3.98%
1 month+41.13%
3 months+14.60%
6 months+15.48%
Current year-0.25%
1 week 117.8
Extreme 117.8
126.9
1 month 76.95
Extreme 76.95
139
Current year 60.45
Extreme 60.45
139
1 year 6.97
Extreme 6.97
139
3 years 4.51
Extreme 4.51
139
5 years 4.51
Extreme 4.51
139
10 years 3.87
Extreme 3.87
139
Manager TitleAgeSince
Chief Executive Officer 68 05/05/2023
Director of Finance/CFO - 02/01/2017
Chief Tech/Sci/R&D Officer - 19/03/2026
Director TitleAgeSince
Chairman - 16/08/2022
Chairman 68 05/05/2023
Director/Board Member 60 11/07/2023
Date Insider Type Main position Quantity % Market Cap.
21/05Fiscal year

Chief Executive Officer

35,456 0.0445%
23/03Fiscal year

Chief Executive Officer

35,456 0.0448%
20/02Free

Director

2,471 0.0032%
Change 5-day change 1-year change 3-year change Capi.($)
-2.28%-6.83%+1,547.46%+646.89% 12.11B
+0.44%+1.31%+4.14%+10.69% 50.73B
-2.55%-4.04%+375.16%+587.22% 39.73B
+1.97%+2.12%+31.36%-4.23% 34.69B
+1.96%-1.39%+21.02%+53.98% 33.21B
-0.06%-4.63%+2.94%+31.65% 26.76B
-2.40%-1.61% - - 16.8B
-0.44%-5.26%+67.12%+122.69% 15.37B
+0.78%+1.16%+15.53%+17.32% 13.78B
+0.02%-2.12%+11.90%-32.80% 12.85B
Average -0.25%-1.78%+230.74%+159.27% 25.6B
Weighted average by Cap. -0.05%-0.78%+155.17%+150.08%

Financials

2026 *2027 *
Net sales 74.92M 85.66M 69.11M 63.83M 121M 8.17B 123M 826M 324M 4.02B 322M 315M 13.84B 82.16M 93.93M 75.78M 69.99M 133M 8.96B 135M 905M 356M 4.41B 353M 345M 15.17B
Net income -265M -303M -245M -226M -429M -28.91B -436M -2.92B -1.15B -14.24B -1.14B -1.11B -48.96B -231M -264M -213M -197M -373M -25.16B -379M -2.54B -999M -12.39B -990M -969M -42.61B
Net Debt -941M -1.08B -868M -802M -1.52B -103B -1.55B -10.37B -4.07B -50.54B -4.04B -3.95B -174B -858M -981M -791M -731M -1.39B -93.52B -1.41B -9.45B -3.71B -46.07B -3.68B -3.6B -158B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
80
Date Price Change Volume
14/07/26 EUR 120.10 -2.28% 121,968
10/07/26 EUR 122.90 +0.24% 100,898
09/07/26 EUR 122.60 +0.41% 88,349
08/07/26 EUR 122.10 -3.71% 126,645
07/07/26 EUR 126.80 -1.63% 179,254
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
122.90EUR
Average target price
138.56EUR
Spread / Average Target
+12.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABVX Stock